Most Recent
The Commonwealth of Australia is weighing a bid to strike out Otsuka Pharmaceutical's defence as the government seeks lost subsidies after an almost seven-year long patent dispute over the antipsychotic drug, Abilify.
Generic drug maker Alphapharm says rival Sanofi-Aventis waited to amend its injector pen patent until the heated IP battle between the two firms had commenced, despite knowing about the amendments for three years.
A judge has expressed frustration at the slow pace of the Sydney light rail class action, forcing both parties to commit to a timetable that will push the proceeding more rapidly towards a final hearing.
Judges do not have the power to approve a class action settlement without first issuing an opt-out notice to group members, the court-appointed contradictor in two shareholder class actions against online fashion retailer Surfstitch told the NSW Supreme Court Thursday.
Actor Geoffrey Rush is seeking to suppress an amended defence by Nationwide News, arguing that if they're made public the amendments could cause him "irreparable harm".
Generic drug maker Alphapharm has lost another bid for documents from Sanofi-Aventis in advance of a hearing on Sanofi's interlocutory application seeking to block the generic drug maker from listing its injector pen on the Pharmaceutical Benefits Scheme.
A leading class action lawyer has defeated an attempt by the Law Society of NSW to revive professional misconduct proceedings against him.
Geoffrey Rush's co-star Eryn Jean Norvill took the stand Tuesday in the actor's defamation case against Nationwide News, telling a court she felt "panicked" and "trapped" by Rush's allegedly inappropriate behaviour during a production of King Lear at the Sydney Theatre Company.
The high-stakes contest to run a shareholder class action against BHP has begun, with lawyers for three competing cases all arguing in Federal Court Monday that there can be only one winner.
A four-day trial against online ticket reseller Viagogo kicked off Monday, with the ACCC describing how the site misled consumers by falsely claiming it was an official ticket vendor, hitting them with a booking fee of around 28 per cent along the way.